United States· US:70748-355_75d51b1e-1d97-40c7-854e-4736e335e048
rivaroxaban granule
A rivaroxaban product containing rivaroxaban, registered in United States by Lupin Pharmaceuticals, Inc.. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Rivaroxaban is registered in 15 of 19 countries.
Countries holding a registration under ATC B01AF01 (rivaroxaban), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Rivaroxaban · ATC B01AF01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rivaroxaban costs, country by country.
Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.67 in France to $5.20 in United States — a ×7.7 gap.
- United States: $5.20 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Rivaroxaban · price per daily dose (20 mg)
USD · FX 28 Sept 2026
- US United States$5.20 (acquisition cost)
- CH Switzerland$2.66
- IT Italy$1.08
- FR France$0.67
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RIVAROXABAN
- Manufacturer
- Lupin Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- B01AF01
- ATC class
- Rivaroxaban
- Defined daily dose
- 20 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1170748355011 BOTTLE in 1 CARTON (70748-355-01) / 1 FOR SUSPENSION in 1 BOTTLE
- ndc1170748-355-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
391 interactions on record for rivaroxaban.
Graded by severity as the source publishes them — 134 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rivaroxaban · interactions on record
391 records
- 134 severe
- 213 moderate
- 2 minor
Most severe, free to view
- LonafarnibA16AX20severe
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
42 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rivaroxaban in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAXALTRA+pharma arzneimittel gmbh, Graz
- SpainBLOMENSY 15 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGEgis Pharmaceuticals Plc.
- PolandAxaltrapharma arzneimittel gmbh
- NetherlandsBlomensy 10 mg filmomhulde tablettenEgis Pharmaceuticals Plc
- SwedenBevimlar 10 mg Filmdragerad tablettSTADA Arzneimittel AG
- SwitzerlandRivarax 10 mg, FilmtablettenDrossapharm AG
- United KingdomRivaroxaban 10mg capsulesAlliance Healthcare (Distribution) Ltd
- FinlandDovequaBausch Health Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 31 EEA countries. Names it is sold under:
- Austria · Rivahib, Rivaroksaban Grindeks
- Belgium · Rivaroxaban, Rivaroxaban Eg
- Bulgaria · Xaboplax Sandoz Pharmaceuticals D.D, Виатрикс
- Cyprus · Enkia, Naxat
- Czechia · Axaltra, Bevimlar
- Germany · Elmardya, Rivadia
- Denmark · Blomensy, Dovequa
- Estonia · Enkia, Kardatuxan
- Spain · Blomensy, Elmardya
- Finland · Blomensy, Dovequa
- France · Elmardya, Rivaroxaban Almus
- United Kingdom (Northern Ireland) · Rivaroxaban, Rivaroxaban Abdi
- Greece · Blomensy, Cinstel
- Croatia · Aban, Bevimlar
- Hungary · Dovequa, Evoxyr
- Ireland · Rivaroxaban Ascend, Rivaroxaban Azure
- Iceland · Agublon, Barsovi
- Italy · Ellebax, Indifaxa
- Liechtenstein · Rivaroxaban Accord, Rivaroxaban Viatris
- Lithuania · Enkia, Kardatuxan
- Luxembourg · Rivaroxaban Eg, Rivaroxaban Eg (Eurogenerics) Nv
- Latvia · Kardatuxan, Mibrex
- Malta · Enkia, Naxat
- Netherlands · Blomensy, Rivaroksaban Grindeks
- Norway · Dovequa, Rivaroxaban Accord
- Poland · Axaltra, Bevimlar
- Portugal · Closderive, Enkia
- Romania · Closderive, Enkia
- Sweden · Bevimlar, Blomensy
- Slovenia · Dovequa, Ribas
- Slovakia · Assubex, Bevimlar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe0a63db-f68d-4636-9604-a5642494dd4b GET /v1/drugs/fe0a63db-f68d-4636-9604-a5642494dd4b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "155",
"substance": "RIVAROXABAN",
"productndc": "70748-355",
"dosage_form": "FOR SUSPENSION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA218195",
"marketing_category": "ANDA"
}See everything about rivaroxaban.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.